Randomized Pragmatic Clinical Trial in a Community-Based Setting Comparing STIOLTO® RESPIMAT® vs. ICS-LABA Plus LAMA in Patients With COPD

Trial Profile

Randomized Pragmatic Clinical Trial in a Community-Based Setting Comparing STIOLTO® RESPIMAT® vs. ICS-LABA Plus LAMA in Patients With COPD

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Olodaterol/tiotropium bromide (Primary) ; Budesonide/formoterol/glycopyrrolate
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms AIRWISE
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 23 Oct 2017 Last checked against ClinicalTrials.gov record
    • 05 Oct 2017 According to a Boehringer Ingelheim Pharmaceuticals media release, first patient has been enrolled.
    • 26 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top